Is Alaunos Therapeutics Inc (TCRT) overvalued? · $5.6M cap
Alaunos Therapeutics Inc (TCRT) is a biotechnology company listed on NASDAQ.
This page asks whether Alaunos Therapeutics Inc (TCRT) looks expensive on cached numbers — not a short thesis.
Latest reported TCRT revenue for 2026-06-30 was $0. Net income was -$2.0M. TCRT currently screens at market cap $5.6M.
TCRT currently screens at market cap $5.6M. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next TCRT 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the TCRT stock page for the full model, not this heading.
Not investment advice.